20th September, 2024

The Dy. General Manager (Listing Dept.)
BSE Limited.,
Corporate Relationship Dept.,
1st Floor, New Trading Ring,
P. J. Towers, Dalal Street, Fort,
Mumbai - 400 001
(BSE Scrip Code: 500420)

The Manager – Listing Dept.,
National Stock Exchange of India Ltd.,
Exchange Plaza, 5th Floor,
Plot No. C/1, G. Block,
Bandra - Kurla Complex, Bandra (E),
Mumbai – 400 051
(NSE Scrip Code: TORNTPHARM)

Dear Sir,

Sub.: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to inform you that the United States Food & Drug Administration (USFDA) conducted a routine GMP inspection of our Formulation manufacturing facility located at Pithampur, Madhya Pradesh between 16-Sep-24 to 20-Sep-24.

At the end of the Inspection, the Agency issued a Form FDA 483 with one observation which is procedural in nature. We will respond to the USFDA within the prescribed time-frame and will work in close collaboration with the Agency to address the observation at the earliest possible time.

We will keep the stock exchanges informed of any material development relating to the above in the future.

Please take the information on record.

Thanking you,

Yours sincerely,

For TORRENT PHARMACEUTICALS LIMITED

CHINTAN M TRIVEDI
Digitally signed by CHINTAN M TRIVEDI
Date: 2024.09.20 12:36:47 +05'30'

CHINTAN M. TRIVEDI
COMPANY SECRETARY